Selective Immunomodulating Microtubule Binding Agents (SIMBA): A Novel Approach To Chemotherapy-Induced Neutropenia

General considerations surrounding the risk of chemotherapy-induced neutropenia in solid tumors.

Considerations for treatment selection for chemotherapy-induced neutropenia.

Implications of severity and sequelae of chemotherapy-induced neutropenia for disease management.

Recommendations for preventing and mitigation infection risk in patients with chemotherapy-induced neutropenia in the adjuvant setting.

Current mitigation and management strategies for chemotherapy-induced neutropenia.

Limitations of current therapies available for the prevention and management of chemotherapy-induced neutropenia.

Strategies for prophylaxis against chemotherapy-induced neutropenia in the setting of metastatic disease.

The rationale for studying plinabulin, a first-in-class selective immunomodulating microtubule binding agent, for the prevention of chemotherapy-induced neutropenia.

An overview of the Protective-1 trial of single-agent plinabulin vs pegfilgrastim after docetaxel in patients with advanced breast cancer, advanced non–small cell lung cancer, and hormone-refractory prostate cancer.

Implications for using plinabulin as prophylaxis against chemotherapy-induced neutropenia alone or in combination with other therapies based on data revealed by the Protective-1 and Protective-2 trials.

A discussion regarding patient selection and indications for using plinabulin, a first-in-class selective immunomodulating microtubule-binding agent, as prophylaxis against chemotherapy-induced neutropenia.

Unmet needs and future directions in the prevention and management of chemotherapy-induced neutropenia.